PMID: 2502417Jan 1, 1989Paper

Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia

European Journal of Clinical Pharmacology
J MölgaardA G Olsson

Abstract

The efficacy and safety of 20 mg simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) and of 16 g cholestyramine daily in the treatment of 34 hypercholesterolaemic patients have been compared after dietary treatment and stratified randomization. The effect of combined treatment with the two drugs was studied in 5 patients with severe hypercholesterolaemia. After 6 weeks of treatment the simvastatin group showed a significantly greater (p less than 0.05) decrease in the mean total plasma cholesterol concentration from 7.88 to 5.48 mmol/l than in the cholestyramine group in whom there was a fall from 7.82 to 6.73 mmol/l. Simvastatin decreased the mean plasma LDL cholesterol concentration from 6.07 to 3.76 mml/l and cholestyramine decreased it from 6.16 to 4.46 mmol/l. Simvastatin also reduced the mean plasma total triglycerides by 24%, VLDL triglycerides by 20% and VLDL cholesterol by 36%, while cholestyramine led to increases in these parameters by 64%, 85% and 63%, respectively. Mean plasma HDL cholesterol concentration and the subfractions HDL2 and HDL3 cholesterol were significantly increased by simvastatin. Simvastatin and cholestyramine reduced the mean plasma apolipoprotein B concentration by 28% and 1...Continue Reading

References

Aug 16, 1986·Lancet·A G OlssonH von Schenk
Apr 15, 1986·The American Journal of Cardiology·J M HoegD L Sprecher
Apr 12, 1985·JAMA : the Journal of the American Medical Association
Jan 1, 1972·Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum·C B Laurell
Dec 1, 1984·The Journal of Clinical Investigation·D R Illingworth, G J Sexton

❮ Previous
Next ❯

Citations

Aug 2, 2003·Gastroenterology·Thierry ClaudelBart Staels
Nov 26, 1999·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·G M ChertowE Slatopolsky
Mar 1, 1992·Journal of Internal Medicine·J MölgaardA G Olsson
Sep 1, 1992·Current Problems in Cardiology·J S Prihoda, D R Illingworth
Aug 28, 2004·Expert Opinion on Investigational Drugs·Thierry ClaudelBart Staels
Aug 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J MölgaardA G Olsson
Jul 23, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Thierry ClaudelFolkert Kuipers
Feb 17, 2005·Endocrinology·Bertrand CariouBart Staels
Mar 1, 1991·DICP : the Annals of Pharmacotherapy·V F Mauro, J L MacDonald
Sep 5, 2009·Molecular and Cellular Biochemistry·Kailash Prasad

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.